Ardelyx, Inc.

Equities

ARDX

US0396971071

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-14 EDT			5-day change	1st Jan Change
6.35 ^USD	-2.16%		-1.55%	+2.42%

05-24	Ardelyx Shares Fall; Chief Commercial Officer Resigns	MT
05-23	Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer	CI

Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer

May 23, 2024 at 04:59 pm

On May 22, 2024, Susan Rodriguez and Ardelyx, Inc. mutually determined that Ms. Rodriguez would resign as the Company?s Chief Commercial Officer. To support the transition, Ms. Rodriguez will remain in an advisory role to the Company through the end of 2024.

Latest news about Ardelyx, Inc.

Ardelyx Shares Fall; Chief Commercial Officer Resigns	05-24	MT
Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer	05-23	CI
Ardelyx Insider Sold Shares Worth $2,522,217, According to a Recent SEC Filing	05-09	MT
Ardelyx Insider Sold Shares Worth $1,831,503, According to a Recent SEC Filing	05-09	MT
Ardelyx Insider Sold Shares Worth $333,574, According to a Recent SEC Filing	05-07	MT
Ardelyx Shares Rise After Q1 Beat	05-03	MT
Wedbush Adjusts Ardelyx's Price Target to $15 From $14, Keeps Outperform Rating	05-03	MT
Top Premarket Gainers	05-03	MT
Transcript : Ardelyx, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Earnings Flash (ARDX) ARDELYX Reports Q1 Revenue $46M, vs. Street Est of $36.4M	05-02	MT
Ardelyx, Inc. Provides IBSRELA Revenue Guidance for the Full Year 2024	05-02	CI
Ardelyx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating	04-17	MT
Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target	04-05	MT
Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy	03-25	CI
Ardelyx Insider Sold Shares Worth $664,978, According to a Recent SEC Filing	03-22	MT
Ardelyx, Inc. announced that it has received $50 million in funding	03-04	CI
Sector Update: Health Care Stocks Mixed Premarket Friday	02-23	MT
Sector Update: Health Care	02-23	MT
Ardelyx's Q4 Swings to Loss; Revenues Down; Shares Down After-Hours	02-23	MT
Ardelyx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Transcript : Ardelyx, Inc., Q4 2023 Earnings Call, Feb 22, 2024	02-22
Ardelyx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Earnings Flash (ARDX) ARDELYX Posts Q4 Revenue $34.4M, vs. Street Est of $34.2M	02-22	MT
Sector Update: Health Care Stocks Slide Late Friday Afternoon	01-12	MT

Chart Ardelyx, Inc.

Duration

Period

More charts

Company Profile

Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Ardelyx, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.35 USD

Average target price

13.83 USD

Spread / Average Target

+117.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARDELYX, INC.	+2.42%	1.49B
VERTEX PHARMACEUTICALS INCORPORATED	+18.15%	124B
REGENERON PHARMACEUTICALS, INC.	+18.02%	112B
ARGENX SE	+5.07%	22.94B
BIONTECH SE	-12.75%	22.22B
BEIGENE, LTD.	-9.86%	17.02B
GENMAB A/S	-14.97%	16.88B
WUXI APPTEC CO., LTD.	-39.94%	16.87B
NEUROCRINE BIOSCIENCES, INC.	+2.80%	13.63B
SAREPTA THERAPEUTICS, INC.	+27.39%	11.61B

Bio Therapeutic Drugs